Italia markets closed
FTSE MIB
27.113,95 +92,91 (+0,34%) Dow Jones
33.274,15 +415,12 (+1,26%) Nasdaq
12.221,91 +208,43 (+1,74%) Nikkei 225
28.041,48 +258,55 (+0,93%) Petrolio
75,70 +1,33 (+1,79%) Bitcoin EUR
26.228,00 +398,48 (+1,54%)
Charles River Laboratories International, Inc. (CRL)
NYSE - Nasdaq Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 04:00PM EDT
Dopo ore:
| Chiusura precedente | 198,03 |
| Aperto | 199,74 |
| Denaro | 195,71 x 800 |
| Lettera | 207,97 x 1300 |
| Min-Max giorno | 198,53 - 202,27 |
| Intervallo di 52 settimane | 181,36 - 308,15 |
| Volume | |
| Media Volume | 575.814 |
| Capitalizzazione | 10,29B |
| Beta (5 anni mensile) | 1,36 |
| Rapporto PE (ttm) | 21,91 |
| EPS (ttm) | 9,21 |
| Prossima data utili | 02 mag 2023 - 08 mag 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 253,83 |
- GlobeNewswire
iVexSol® Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors
LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: CRL) and Asahi Kasei Medical, a division of Asahi Kasei (NYSE: AHKSY), join existing investors which include Casdin Capital and BioLife Solutions (Nasdaq: BLFS) to close Series A financing at a total of
© 2023 Yahoo. Tutti i diritti riservati.
